Hancock Whitney’s Amphastar Pharmaceuticals AMPH Stock Holding History

Hancock Whitney’s Portfolio AMPH Stock Details AMPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-5,109	Closed	-$248K	–	633
2024 Q3	$248K	Sell	5,109 -629	-11%	-$27.6K	0.01%	569
2024 Q2	$230K	Sell	5,738 -369	-6%	-$15.3K	0.01%	566
2024 Q1	$268K	Buy	6,107 +2,252	+58%	+$116K	0.01%	567
2023 Q4	$238K	Buy	+3,855	New	+$203K	0.01%	586
2023 Q3	–	Sell	-3,998	Closed	-$230K	–	620
2023 Q2	$230K	Buy	+3,998	New	+$177K	0.01%	580

Other funds holding AMPH

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

Pacer Advisors Malvern, Pennsylvania $39.3B AUM 27.96% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return

EIP

Epoch Investment Partners New York $17.6B AUM 34.17% 1-Year Est. Return

BTW

Boston Trust Walden Boston, Massachusetts $13.1B AUM 24.63% 1-Year Est. Return

Hancock Whitney's AMPH Position: Q4 2024 in Review

Hancock Whitney sold out of Amphastar Pharmaceuticals (AMPH) in Q4 2024, closing a stake of 5,109 shares — an estimated $248K sold.

Hancock Whitney first reported a position in AMPH in Q2 2023 and held it in 5 quarters. The position peaked at $268K in Q1 2024. 263 funds tracked by Wall St. Rank hold AMPH as of Q4 2024.

Hancock Whitney reported no remaining Amphastar Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
Hancock Whitney sold 5,109 Amphastar Pharmaceuticals shares in Q4 2024, an estimated $248K.
Hancock Whitney first reported a position in Amphastar Pharmaceuticals in Q2 2023 and held it in 5 quarters.
Hancock Whitney's Amphastar Pharmaceuticals position peaked at $268K in Q1 2024.
263 funds tracked by Wall St. Rank held Amphastar Pharmaceuticals as of Q4 2024.

Based on Hancock Whitney's 13F filing for Q4 2024, filed 14 Feb 2025.